COR

Cencora (NYSE: COR) agreed to acquire American Oncology Network to expand its community-based cancer care footprint.

COR's Q4 earnings are likely to benefit from strong specialty pharma demand and MSO growth, but pricing pressures and higher interest costs may weigh on results.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2026.

Cencora (COR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

COR's $2.4B acquisition of AON aims to expand its oncology services platform, strengthen community cancer care and support long-term growth.

Cencora is scheduled to release its fourth-quarter results next month, with analysts projecting double-digit earnings growth.

Cencora (COR) has moved to take control of American Oncology Network (OTCPK:AONC) by signing a deal to acquire the remaining 96% it does not own for an enterprise value of $2.4b.

Cencora has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6% to $341.69 per share while the index has gained 9.7%.

Cencora has delivered a powerful long run for shareholders, and the question now is whether the current share price lines up with the cash the business can generate.

New Amazon sales channel expands COR's sales reach beyond Worksport's web platform, to the world's largest retail market as Worksport targets growth in broader portable power, home backup and off-grid energy. WEST SENECA, NY / ACCESS...